Study of KRN951 in Patients With Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-08-31

Study Completion Date

2016-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to assess the safety and tolerability of KRN951 administered to patients with solid tumors. In the single dose period, patients in each cohort will receive one oral dose of KRN951 in the first day, followed by a 6-day rest period during which no treatment is received. After that, patients in each cohort will receive one oral dose of KRN951 daily over a 21-day treatment period, followed by a 7-day rest period during which no treatment is received. Treatment will be continued in the absence of disease progression or unacceptable adverse events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase I Study of BMS-690514 in Japanese Patients With Solid Tumors

NCT00516451

Cancer

COMPLETED PHASE1

Safety Study to Evaluate KW-2450 in Subjects With Advanced Solid Tumor

NCT00921336

Solid Tumor

COMPLETED PHASE1

A Phase I Open Label Dose Escalation Study for the Safety and Tolerability of AZD2171 in Solid Tumors in Japan

NCT00503477

Advanced Solid Tumor

COMPLETED PHASE1

A Phase 1 Study of ARQ 197 in Patients With Solid Tumors

NCT00609921

Cancer

COMPLETED PHASE1

Dose Escalation of HSP990 in Japan/Korea

NCT01064089

Advanced Solid Tumors

TERMINATED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

KRN951

Group Type EXPERIMENTAL

KRN951

Intervention Type DRUG

Orally once daily administration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KRN951

Orally once daily administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Signed written informed consent
* Solid tumors to be unresponsive to, or untreatable by standard therapies
* ≥ three-month life expectancy
* Eastern Cooperative Oncology Group Performance Status score of 0, 1 or 2

Exclusion Criteria

* Hematologic abnormality
* Myocardial infarction or clinically symptomatic left ventricular failure
* Active hypertension or controllable hypertension more than 3 antihypertensive medications
* Symptomatic CNS metastasis
* Unhealed wounds
* Active infections
* Hepatic or renal functional disorder
* Any of the HBs antigen, HCV antibody and HIV antibody positivity
* Prior use of any chemotherapy, radiotherapy, immunotherapy or surgery within four weeks previous to first dose of study drug
* Pregnant or lactating women
* Women of childbearing potential and fertile men, unless willing to use adequate contraceptive protection

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No